Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$128 Mln
P/E Ratio
--
P/B Ratio
2.68
Industry P/E
--
Debt to Equity
0
ROE
-0.56 %
ROCE
-54.82 %
Div. Yield
0 %
Book Value
1.45
EPS
-1
CFO
$-129.63 Mln
EBITDA
$-147.73 Mln
Net Profit
$-158.76 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sera Prognostics Inc (SERA)
| -58.35 | -13.74 | -47.20 | -65.23 | 13.80 | -- | -- |
|
BSE Sensex*
| 1.91 | 3.69 | 5.15 | 9.10 | 11.25 | 21.08 | 11.16 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Sera Prognostics Inc (SERA)
| 35.78 | 374.60 | -81.66 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 43.31 | 7,285.87 | 37.1 | 21.8 | |
| 165.01 | 5,936.91 | 21.13 | 13.21 | |
| 142.37 | 5,656.67 | 20.01 | 27.01 | |
| 74.93 | 6,837.38 | 25.33 | 31.45 |
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test... given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Address: 2749 East Parleys Way, Salt Lake City, UT, United States, 84109 Read more
President, CEO & Director
Ms. Evguenia Lindgardt M.B.A.
President, CEO & Director
Ms. Evguenia Lindgardt M.B.A.
Headquarters
Salt Lake City, UT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sera Prognostics Inc (SERA) stood at $ 73 Mln as on 31-Dec-24
The share price of Sera Prognostics Inc (SERA) is $3.39 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Sera Prognostics Inc (SERA) has given a return of 13.8% in the last 3 years.
Sera Prognostics Inc (SERA) has a market capitalisation of $ 128 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Sera Prognostics Inc (SERA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sera Prognostics Inc (SERA) and enter the required number of quantities and click on buy to purchase the shares of Sera Prognostics Inc (SERA).
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Address: 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
The CEO & director of Ms. Evguenia Lindgardt M.B.A.. is Sera Prognostics Inc (SERA), and CFO & Sr. VP is Ms. Evguenia Lindgardt M.B.A..
There is no promoter pledging in Sera Prognostics Inc (SERA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
738
|
|
|
690
|
|
|
589
|
|
|
561
|
| Sera Prognostics Inc (SERA) | Ratios |
|---|---|
|
Return on equity(%)
|
-55.78
|
|
Operating margin(%)
|
-42688.31
|
|
Net Margin(%)
|
-42724.68
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sera Prognostics Inc (SERA) was $0 Mln.
$-0.01
(
